Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anadolu Univ. EGFR compound 13
- Development stage
- Unknown
- Lead developer
- Anadolu University
01
Overview
Anadolu Univ. EGFR compound 13: sourced facts only. name: "The most effective EGFR inhibitor in this series was found as compound 13, followed by compounds 17 and 16." [PMID:39047611]; target: "The most effective EGFR inhibitor in this series was found as compound 13, followed by compounds 17 and 16." [PMID:39047611]; developer: "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey." [PMID:39047611]
02
Targets
Beyond the preview
Go deeper on Anadolu Univ. EGFR compound 13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anadolu Univ. EGFR compound 13.